NDAORALSOLUTIONPriority Review
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
28
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEKINIST (trametinib) is an oral small-molecule MEK inhibitor developed by Novartis and approved in March 2023. It is indicated for treatment of multiple cancer types including melanoma, non-small cell lung cancer, pancreatic cancer, and various hematologic malignancies, as well as non-oncologic conditions including neurofibromatosis type 1 and amyotrophic lateral sclerosis. The drug works by inhibiting mitogen-activated protein kinase (MEK) signaling, a pathway frequently dysregulated in cancer and genetic disorders. It represents a targeted therapy option in the kinase inhibitor landscape, often used as monotherapy or in combination regimens.
$0.2BPart D
4.9 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (28)
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Started Feb 2026
30 enrolled
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+16 more
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
Started Dec 2025
221 enrolled
CancerBRAF V600 MutationMelanoma+3 more
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
Started Aug 2025
45 enrolled
Ras/MAPK Pathway Vascular AnomaliesVascular AnomaliesVascular Anomaly
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Started Jul 2024
60 enrolled
KRAS Mutation-Related TumorsAdvanced Lung CancerRefractory Tumor
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Started Apr 2024
78 enrolled
Advanced or Metastatic NRAS-mutant Melanoma
Worked on MEKINIST at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.